News
For the latest media releases and news about Pharmaxis Ltd, please select from the following articles. Material news announcements made by Pharmaxis are first filed with the Australian Securities Exchange (ASX) and are also available on the ASX website.
Scottish Medicines Consortium Accepts Bronchitol For Use In Cystic Fibrosis Patients
Pharmaceutical company Pharmaxis (ASX:PXS) today announced that the Scottish Medicines Consortium (SMC) has accepted Bronchitol® (mannitol dry powder for inhalation) for use by the National Health Service in Scotland. Bronchitol is licensed for the treatment of adult cystic fibrosis (CF) patients aged 18 years and above as an add-on therapy to best standard of care.
Bronchitol is the first non-antibiotic therapy to be accepted by the SMC for the treatment of CF.
The recommendation enables Scottish adults that are in need of new treatment options for their CF, to gain access to Bronchitol. Bronchitol is accepted for use as an add-on to best standard of care, in adults who are not currently using dornase alfa due to lack of response, intolerance or ineligibility and who have a rapidly declining lung function and in whom other osmotic agents are considered unsuitable.
Read full media release - pdf